Christopher Chan
Family · Los Angeles, CANPI 1790037356
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Novo Nordisk at 24.7% of the total. Reporting peaked in 2023 at $7,098 and has fallen 65.9% since, to $2,421 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $187.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$6K
- Sanofi$6K
- CSL Behring$4K
- Genentech USA, Inc.$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Pfizer$1K
- plus $1K from 8 others
What the payments were for
- Consulting fees$12,97953%
- Speaking & faculty fees$6,51927%
- Travel & lodging$1,5887%
- Food & beverage$3,13513%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $6,002 |
| Sanofi | 14 | $5,785 |
| CSL Behring | 18 | $4,142 |
| Genentech USA, Inc. | 7 | $4,072 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $1,929 |
| Pfizer | 17 | $1,338 |
| Bayer | 20 | $434 |
| Genentech, Inc. | 5 | $197 |
| Octapharma USA, Inc. | 4 | $161 |
| Biomarin Pharmaceutical Inc. | 3 | $98 |
| HEMA Biologics, LLC | 2 | $62 |
| Kedrion Biopharma, Inc. | 2 | $61 |
| Masimo Corporation | 1 | $25 |
| Grifols USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,324 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 16 | $59,325 |
| JardianceEmpagliflozin | 13 | $7,471 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $681 |
| Oxycodone Hcl | 14 | $180 |
| Valsartan | 15 | $145 |
| Ibuprofen | 26 | $105 |
| Nifedipine ErNifedipine | 12 | $94 |
| Atorvastatin Calcium | 12 | $61 |
| Ondansetron Hcl | 12 | $53 |
| Lisinopril | 22 | $51 |
| Metformin Hcl | 11 | $46 |
| Trazodone Hcl | 12 | $35 |
| Temazepam | 12 | $34 |
| Metoprolol Succinate | 11 | $32 |
| Chlorhexidine Gluconate | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Other family in Los Angeles
- Annette ShonLos Angeles$406K
- Phyllis CasonLos Angeles$187K
- Theodore SolomonLos Angeles$131K
- Angela SarffLos Angeles$51K
- Karla MenjivarLos Angeles$36K
- Janet GripshoverLos Angeles$30K
- Jualynda SmithLos Angeles$28K
- Phoebedel ReyesLos Angeles$26K
- Ayana ElliottLos Angeles$25K
- Lori RobertsonChino Hills$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.